Dendritic cells play a key role in activation of the immune system as potent antigen-presenting cells. This pivotal position, along with the ability to generate dendritic cells from monocytes and ready uptake of antigen, makes them an intriguing vehicle for immunotherapy for a variety of indications. Since the first reported trial using dendritic cells in 1995, they have been used in trials all over the world for a plethora of indications. Monocyte-derived dendritic cells are generated from whole blood or apheresis products by culturing enriched monocytes in the presence of interleukin (IL)-4 and granulocyte-macrophage colony-stimulating factor (GM-CSF). A variety of methods can be used for enrichment of monocytes for generation of clinical-grade dendritic cells and are summarized herein.

中文翻译：

---

制造用于免疫疗法的树突状细胞：单核细胞富集。

树突状细胞作为有效的抗原呈递细胞在免疫系统激活中起关键作用。这种关键的位置，以及从单核细胞生成树突状细胞和易于吸收抗原的能力，使其成为进行各种适应症免疫治疗的诱人载体。自从1995年首次报道使用树突状细胞的试验以来，它们已在全世界的试验中用于多种适应症。通过在白介素（IL）-4和粒细胞巨噬细胞集落刺激因子（GM-CSF）的存在下培养富集的单核细胞，从全血或单采血液分离术产物中产生单核细胞衍生的树突状细胞。多种方法可用于富集单核细胞以产生临床级树突状细胞，并且在本文中进行了概述。